Wiley has announced a collaboration with IQVIA that has created a one-stop solution designed to simplify and accelerate the Clinical Outcome Assessment (COA) implementation process. The collaboration brings together Wiley’s content resources and IQVIA’s clinical research capabilities to provide pharmaceutical companies, research institutions, and contract research organizations with easier access to validated COA instruments and comprehensive support services. The one-stop approach is structured to streamline the COA lifecycle, reduce reliance on multiple vendors, ensure consistent quality, and improve compliance with regulatory and scientific standards.
COA licensing has traditionally required coordination among several separate providers, including publishers for instrument permissions, translation vendors for multilingual versions, and consultants for scoring and implementation. This fragmented process often takes months and can affect trial timelines, regulatory compliance, and quality assurance. The joint Wiley–IQVIA solution shortens and simplifies these steps by offering integrated COA licensing and implementation under a single contract, supported directly by the rights holder to help ensure scientific integrity and copyright compliance.
Five Wiley-managed COA instruments are included in the first phase of the agreement, with plans to expand access to Wiley’s broader portfolio of more than 100 COAs and to offer full lifecycle support services for many of these instruments by the end of 2026. These instruments cover key areas of clinical research, including anxiety, depression, pediatric cancer functional status, lupus-related organ damage, and physical sexual maturity assessment.
The collaboration combines Wiley’s academic publishing expertise with IQVIA’s operational and scientific capabilities in COA development and implementation. Under the arrangement, validated instruments are made accessible through Wiley, while IQVIA provides integrated support for translation, digital migration, and implementation. Translated versions will be available through IQVIA’s eCOA platform.
The organizations have highlighted that pharmaceutical companies require high confidence in the scientific validity of outcome measures because trial results, research investment, and regulatory decisions depend on them. The alliance is intended to streamline access to validated instruments across the clinical trial lifecycle and to support efficient study design and execution. It is also framed as a way to extend advanced COA capabilities to the drug and device development sectors, supporting timely and reliable research outcomes.
The initiative demonstrates Wiley’s ability to incorporate established research content into partner clinical platforms and aligns with the company’s broader strategy to expand its presence in corporate R&D markets through integrated, technology-enabled solutions for pharmaceutical and biotechnology organizations.
Click here to read the original press release.
